| Biotechnology Industry | Healthcare Sector | Dr. Peter Joseph Sargent CEO | LSE Exchange | GB00BDR6W943 ISIN |
| United Kingdom Country | 10 Employees | - Last Dividend | - Last Split | - IPO Date |
Physiomics Plc is a consulting firm that specializes in providing a range of quantitative pharmacology and computational biology services to pharmaceutical companies. Operating primarily within the United Kingdom, the United States, and the European Union including Switzerland, Physiomics combines its expertise in modeling, simulation, and data analysis to advance oncology research and development. The company leverages its proprietary Virtual Tumour predictive software to facilitate these processes. With a focus on the burgeoning field of personalized medicine, Physiomics is dedicated to developing innovative technology solutions. Founded in 2001, the company has established its headquarters in Oxford, United Kingdom, marking its place within the global pharmaceutical consulting sector.
Physiomics Plc offers a diversified portfolio of products and services targeted at enhancing pharmaceutical R&D through quantitative analysis and predictive modeling. These include: